UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2110-9
Program Prior Authorization/Medical Necessity
Medication Adynovate® (antihemophilic factor [recombinant], pegylated)
P&T Approval Date 10/2016, 10/2017, 10/2018, 10/2019, 9/2020, 9/2021, 9/2022, 9/2023,
9/2024
Effective Date 12/1/2024
1. Background:
Adynovate (antihemophilic factor [recombinant], pegylated) is a recombinant antihemophilic
factor indicated in adults and children with hemophilia A (congenital Factor VIII deficiency)
for:1
On-demand treatment and control of bleeding episodes
o
Routine prophylaxis to reduce the frequency of bleeding episodes
o
Perioperative management
o
Adynovate is not indicated for the treatment of von Willebrand disease.
2. Coverage Criteriaa:
A. Initial Authorization
1. Adynovate will be approved based on all of the following criteria:1-3
a. Diagnosis of hemophilia A
-AND-
b. Patient is not a suitable candidate for treatment with shorter acting half-life Factor VIII
(recombinant) products [Advate, Kogenate FS, Kovaltry, Novoeight, Nuwiq, or
Recombinate] as attested by the prescriber
-AND-
c. One of the following:
(1) Both of the following:
(a) Patient is not to receive routine infusions more frequently than 2 times per week
-AND-
(b) Patient is not to receive a routine dose greater than 50 IU/kg
© 2024 UnitedHealthcare Services, Inc.
1
-OR-
(2) All of the following
(a) Patient is less than 12 years of age
-AND-
(b) Patient is not to receive routine infusions more frequently than 2 times per week
-AND-
(c) Patient is not to receive a routine dose greater than 70 IU/kg
Authorization of therapy will be issued for 12 months
B. Reauthorization
1. Adynovate will be approved based on both of the following criteria:
a. Documentation of positive clinical response to Adynovate therapy
-AND-
b. One of the following:
(1) Both of the following:
(a) Patient is not to receive routine infusions more frequently than 2 times per
week
-AND-
(b) Patient is not to receive a routine dose greater than 50 IU/kg
-OR-
(2) All of the following
(a) Patient is less than 12 years of age
-AND-
(b) Patient is not to receive routine infusions more frequently than 2 times per
week
-AND-
(c) Patient is not to receive a routine dose greater than 70 IU/kg
© 2024 UnitedHealthcare Services, Inc.
2
Authorization of therapy will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
4. References:
1. Adynovate® [package insert]. Lexington, MA: Baxalta US, Inc., August 2023.
2. Hoots WK, Shapiro AD. Hemophilia A and B: Routine management including prophylaxis.
In: UpToDate, Waltham, MA, 2024.
3. Recommendations Concerning Products Licensed for the Treatment of Hemophilia and
Selected Disorders of the Coagulation System. MASAC Document #284, April 11, 2024.
Program Prior Authorization/Medical Necessity - Adynovate
Change Control
10/2016 New program.
10/2017 Updated background and criteria to note updated indication. Revised
formatting without changes to clinical intent outside of new indication.
Updated state mandate verbiage. Updated references.
10/2018 Annual review with no changes to coverage criteria. Updated
reference.
10/2019 Annual review with no changes to coverage criteria. Updated
reference.
9/2020 Modified criteria aligning with coverage criteria for other covered
extended half-life recombinant factors. Removed exclusion notation
since addition to coverage. Updated references.
9/2021 Annual review with no changes to coverage criteria. Updated
reference.
9/2022 Annual review with no changes to coverage criteria. Updated
references.
9/2023 Annual review. Modified physician attestation to prescriber attestation.
Updated references.
9/2024 Annual review with no changes to coverage criteria. Updated
references.
© 2024 UnitedHealthcare Services, Inc.
3